Unknown

Dataset Information

0

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.


ABSTRACT: The objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia. Post-hoc, observed-case analysis included pooled data from six studies on 40-160 mg/day lurasidone; two studies included active comparators (2-6 mg/day risperidone or 200-800 mg/day quetiapine XR). Overall, 593 patients completed 12 months of treatment (N=471 lurasidone, N = 89 risperidone, N = 33 quetiapine XR). The mean baseline weight was 72.8, 80.8, and 72.4 kg in the lurasidone, risperidone, and quetiapine XR groups, respectively. The mean weight change at month 12 was -0.4 kg with lurasidone, +2.6 kg with risperidone, and +1.2 kg with quetiapine XR. Weight gain of at least 7% from study baseline was observed in 16.0, 25.8, and 15.2% of patients, and weight loss of at least 7% was seen in 18.5, 6.7, and 9.1% of patients treated with lurasidone, risperidone, and quetiapine XR, respectively. A shift from normal/underweight baseline BMI status to overweight/obese at month 12 occurred in 10.2, 27.6, and 15.0% of patients in the lurasidone, risperidone, and quetiapine XR groups, respectively. Conversely, 14.3, 1.7, and 7.7% of patients, respectively, shifted from overweight/obese to normal/underweight. In summary, a low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months.

SUBMITTER: Meyer JM 

PROVIDER: S-EPMC4593468 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.

Meyer Jonathan M JM   Mao Yongcai Y   Pikalov Andrei A   Cucchiaro Josephine J   Loebel Antony A  

International clinical psychopharmacology 20151101 6


The objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia. Post-hoc, observed-case analysis included pooled data from six studies on 40-160 mg/day lurasidone; two studies included active comparators (2-6 mg/day risperidone or 200-800 mg/day quetiapine XR). Overall, 593 patients completed 12 months of treatment (N=471 lurasidone, N = 89 risperidone, N = 33 quetiapine XR). The mean baseline weight was 72.8, 80.8, an  ...[more]

Similar Datasets

| S-EPMC4411643 | biostudies-literature
| S-EPMC3528473 | biostudies-literature
| S-EPMC7188269 | biostudies-literature
| S-EPMC4850471 | biostudies-literature
| S-EPMC7296806 | biostudies-literature
| S-EPMC8647158 | biostudies-literature
| S-EPMC6299317 | biostudies-literature
| S-EPMC5606317 | biostudies-literature
| S-EPMC5532271 | biostudies-literature
| S-EPMC5069590 | biostudies-literature